Last reviewed · How we verify

Folate plus metformin

University Magna Graecia · FDA-approved active Small molecule Quality 5/100

Folate plus metformin is a Small molecule drug developed by University Magna Graecia. It is currently FDA-approved.

Folate plus metformin, marketed by University Magna Graecia, is a combination therapy currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports market stability. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameFolate plus metformin
SponsorUniversity Magna Graecia
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Folate plus metformin

What is Folate plus metformin?

Folate plus metformin is a Small molecule drug developed by University Magna Graecia.

Who makes Folate plus metformin?

Folate plus metformin is developed and marketed by University Magna Graecia (see full University Magna Graecia pipeline at /company/university-magna-graecia).

What development phase is Folate plus metformin in?

Folate plus metformin is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing